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Abstract
Objective: The identification of new causal risk factors has the potential to improve cardiovascular disease (CVD) risk 
prediction and the development of new treatments to reduce CVD deaths. In the general population, we sought to 
determine whether cortisol is a causal risk factor for CVD and coronary heart disease (CHD).
Design and methods: Three approaches were adopted to investigate the association between cortisol and CVD/CHD. 
First, we used multivariable regression in two prospective nested case-control studies (total 798 participants, 313 
incident CVD/CHD with complete data). Second, a random-effects meta-analysis of these data and previously published 
prospective associations was performed (total 6680 controls, 696 incident CVD/CHD). Finally, one- and two-sample 
Mendelian randomization analyses were performed (122,737 CHD cases, 547,261 controls for two-sample analyses).
Results: In the two prospective nested case–control studies, logistic regression adjusting for sex, age, BMI, smoking and 
time of sampling, demonstrated a positive association between morning plasma cortisol and incident CVD (OR: 1.28 
per 1 SD higher cortisol, 95% CI: 1.06–1.54). In the meta-analysis of prospective studies, the equivalent result was OR: 
1.18, 95% CI: 1.06–1.31. Results from the two-sample Mendelian randomization were consistent with these positive 
associations: OR: 1.06, 95% CI: 0.98–1.15.
Conclusions: All three approaches demonstrated a positive association between morning plasma cortisol and incident 
CVD. Together, these findings suggest that elevated morning cortisol is a causal risk factor for CVD. The current data 
suggest strategies targeted at lowering cortisol action should be evaluated for their effects on CVD.
Introduction
Despite lifestyle improvements and the successful 
targeting of cardiovascular disease (CVD) risk factors, 
such as hypercholesterolaemia (1) and hypertension 
(2), CVD is a leading cause of death in high-income 
countries and increasingly so in low- and middle-
income countries (3). The identification of new causal 
risk factors, such as elevated morning plasma cortisol, 
has the potential to improve CVD risk prediction 
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and the development of new treatments to reduce 
CVD deaths.
Cortisol is a glucocorticoid produced by the adrenal 
glands, which is responsible for cardiovascular and 
metabolic adaptations during stress. Plasma cortisol has 
a circadian rhythm with a peak on waking and then 
declining throughout the day. Inappropriately sustained 
cortisol production in patients with tumours causing 
Cushing’s syndrome results in abdominal obesity, 
hyperglycaemia, hypertension and dyslipidaemia and 
is associated with a four-fold increase in mortality 
rate, predominantly due to accelerated atherosclerosis 
and increased CVD (4, 5). A similar higher rate of 
CVD has been documented in patients prescribed 
exogenous glucocorticoid therapy at supra-physiological 
doses (6).
Several population-based cross-sectional studies 
have reported morning plasma levels of cortisol to 
be positively associated with plasma glucose, blood 
pressure and other cardiovascular risk factors (7, 8, 9, 10). 
Associations have also been found between cortisol and 
markers of subclinical atherosclerosis including carotid 
plaques and coronary artery calcification (11). Evidence 
of an association between circulating cortisol levels and 
CVD events is, however, less conclusive, with studies to 
date mostly being cross-sectional (12). Three prospective 
cohort studies have reported a positive association 
between morning plasma cortisol and CVD, but effects 
were imprecisely estimated due to the small study sizes 
(number of incident CVD cases between 63 and 320) (13, 
14, 15). Larger prospective studies, and the use of genetic 
predictors of morning plasma cortisol as instrumental 
variables in Mendelian randomization analyses (16), 
are required to address whether cortisol is a causal risk 
factor for CVD.
A recent genome-wide association meta-analysis 
(GWAMA) study identified independent variants in one 
locus on chromosome 14 which together explained 
0.5% of the variance in morning plasma cortisol in 
European populations (17). These findings provide 
instrumental variables for a Mendelian randomization 
analysis of the effect of morning plasma cortisol 
on CVD (16).
We hypothesised that elevated morning plasma 
cortisol is a causative risk factor for incident CVD and 
tested this in multiple prospective studies and using 
Mendelian randomization.
Methods
New prospective cohort studies of plasma cortisol 
and CVD
The Northern Sweden VIP, MONICA and MSP study
A prospective case–control study of fatal and non-fatal 
myocardial infarction (MI) and stroke was nested within 
the combined data from three studies conducted in the 
same population (Northern Sweden) using identical 
study protocols (the Västerbotten Intervention Program 
(VIP) (18), the Northern Sweden MONItoring Of trends 
and Determinants in CArdiovascular Disease (MONICA) 
survey and the Mammary Screening Program (MSP); 
details are provided in Supplementary material, see 
section on supplementary data given at the end of this 
article) (19, 20). Incident cases were selected after removal 
of all prevalent cases, and two controls for every case were 
matched to cases by sex, age (median difference in age 
0.33 years), study and date of baseline assessment (median 
difference in baseline assessment date 79 days). The study 
was approved by the Research Ethics Committee of Umeå 
University and informed consent was obtained from 
all participants.
Cortisol was measured by immunoassay on plasma 
samples obtained at the baseline assessment after at least 
4 h of fasting and stored at −80°C (21). Genotyping of 
three SNPs from the GWAMA which together contributed 
most to morning plasma cortisol (rs12589136, 
rs2749527, rs11621961) (17) was performed on the 
OpenArray platform.
British Women’s Heart and Health Study (BWHHS)
BWHHS is a prospective cohort study of 4286 women who 
were randomly selected from 23 British towns between 
1999 and 2001 and who were aged 60–79 years at baseline; 
details are provided in Supplementary material (22). We 
used participants from a prospective case–control study of 
coronary heart disease (CHD) nested within this cohort, 
as previously described (23). Incident cases of CHD were 
selected, and two controls were randomly selected, within 
5-year age groups of the cases, from women without CHD 
at the baseline assessment and who had been followed 
up over the same time as the cases without a CHD event.
Serum cortisol levels were determined by radio-
immunoassay (MP Biomedicals, UK; intra-assay CV 
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5.1–7.0%, inter-assay CV 6.0–7.9%) on blood samples 
obtained at the baseline examination after a minimum 
6-h fast between 08:00 h and 17:00 h. The BWHHS has 
Local- and Multi-Centre Research Ethics Committee 
(LREC and MREC) approvals and all participants provided 
written informed consent.
Statistical analysis
In the VIP, MONICA and MSP cohort, conditional logistic 
regression models, adjusting for matching variables (age 
and baseline assessment date), smoking, body mass index 
(BMI) and time of sampling (continuous variable as number 
of minutes since the earliest sampling time) were used to 
investigate the effect of a 1 s.d. increase in morning plasma 
cortisol on CVD. Sex and study did not vary between 
matched cases and controls and so were not included 
in the model. The controls in BWHHS were matched to 
cases within 5-year age bands meaning control for the 
matching factor can be obtained, with no loss of validity 
and possible increase in precision, using (unconditional) 
logistic regression as there are no problems of sparse data 
(24). In BWHHS, logistic regression models, adjusting for 
the matching variable (age), smoking, BMI and time of 
sampling were used to investigate the effect of a 1 s.d. 
increase in morning plasma cortisol on CHD.
The main analysis used samples collected before 
11:00 h, adjusted for time of sampling, as used for the 
GWAMA which identified genetic variants associated with 
morning plasma cortisol (17). The impact of missing data 
was investigated using multiple imputation by chained 
equations (25); details of this procedure and all additional 
analyses are in the Supplementary material. Analyses were 
performed using Stata v.14 (26). We report exact two-sided 
P values throughout.
Meta-analysis of prospective studies
The multivariable regression meta-analysis of prospective 
studies combined data from the unpublished analyses of 
VIP, MONICA and MSP (fatal and non-fatal CVD) and 
BWHHS (fatal and non-fatal CHD) described earlier, as 
well as published data for morning plasma cortisol from 
the Caerphilly Study (fatal and non-fatal ischaemic heart 
disease (IHD)) (13) and the Vietnam Experience Study 
(fatal CVD) (15). Details of these cohorts are available in 
the Supplementary material. We were not able to include 
a third published prospective study (14) because the 
necessary data were not available.
Statistical analysis
A random-effects (DerSimonian–Laird) method was used 
to pool the maximally confounder adjusted (for each 
study) association of 1 s.d. higher morning plasma cortisol 
with CVD/CHD. A random-effect method was used as we 
were aware of clinical/study heterogeneity (i.e. different 
confounder adjustment, outcome definitions and 
genders/geographical locations), and statistical evidence 
of heterogeneity between studies was assessed with chi-
squared goodness of fit and the I2 statistic, together with 
its 95% CI (27). Sensitivity analyses are described in the 
Supplementary material.
One- and two-sample Mendelian 
randomization analyses
Mendelian randomization analyses use genetic variants as 
a proxy for environmental exposures. As genetic variants 
are assigned at conception and tend not to be associated 
with other behavioural, social or physiological factors, 
these analyses are less likely to be affected by reverse 
causation or confounding than conventional observational 
studies (16). The genetic instrument for morning plasma 
cortisol comprised three SNPs (rs12589136, rs2749527, 
rs11621961) in low linkage disequilibrium (r2 < 0.3), each 
associated independently with morning plasma cortisol 
in the CORtisol NETwork (CORNET) GWAMA (n = 12,597) 
(17). Biochemical investigation of these SNPs have also 
shown them to be associated with variation in total 
cortisol-binding activity in plasma (17). The three SNPs 
explain approximately 0.5% variation in morning plasma 
cortisol levels and are located on chromosome 14 at a 
locus containing the SERPINA6 gene. The SERPINA6 gene 
codes for corticosteroid-binding globulin (CBG) which 
binds to cortisol in the blood. To assess the potential of 
horizontal pleiotropy, where a genetic variant influences 
multiple outcomes through independent pathways, 
we investigated the association of these SNPs with 
confounders included in the multivariable prospective 
analysis in the VIP, MONICA and MSP cohort and with 
cardiovascular risk factors in publicly available GWAS 
consortia.
One-sample Mendelian randomization analysis in VIP, 
MONICA and MSP cohort
The causal estimate was derived using the two-stage 
method comprising a first-stage regression of the exposure 
on the SNP and a second-stage regression of the outcome 
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on the fitted values of the exposure from the first stage. 
Further details are available in the Supplementary 
material. This provides the log OR for CVD per 1 s.d. 
increase in morning plasma cortisol due to each SNP. The 
effects of each SNP were combined in a random-effects 
meta-analysis.
Two-sample Mendelian randomization analysis
A two-sample Mendelian randomization approach (28), 
using publicly available data, was used to estimate 
the causal effect of morning plasma cortisol on CHD. 
We investigated the association between the genetic 
instrument for morning plasma cortisol and risk of 
CHD in a meta-analysis of 34,541 CHD cases and 
261,984 controls of UK Biobank and 88,192 cases and 
162,544 controls from CARDIoGRAMplusC4D (29). 
In the main analyses the causal effect of morning 
plasma cortisol on CHD was estimated for each SNP 
individually using the Wald ratio method (30) and then 
combined in a random-effects meta-analysis. Additional 
analyses described in the Supplementary material were 
performed to investigate the robustness of this causal 
estimate and any potential pleiotropic effects. The 
summary GWAS data for morning plasma cortisol and 
CHD can be downloaded from https://datashare.is.ed.
ac.uk/handle/10283/2787 and https://data.mendeley.
com/datasets/gbbsrpx6bs/1 respectively.
Results
New prospective cohort studies of plasma cortisol 
and CVD
The Northern Sweden VIP, MONICA and MSP study
There were 905 cases and 1717 matched controls (93 
cases with one control, 812 cases with two controls) 
included in the analysis. Of the 905 cases of CVD, there 
were 536 cases of MI and 369 cases of stroke, including 
fatal and non-fatal events. Median time to CVD event 
was 3 years 9 months. Those with CHD were more likely 
to have hypertension and higher BMI, total cholesterol, 
triglycerides and fasting glucose and to smoke tobacco 
(Table 1). Owing to the high proportion with missing data 
(Supplementary Table 4), analyses were performed for all 
participants, those with complete data, and in a dataset 
with imputation of missing data. Time of blood sampling 
was not recorded in 52% of participants, who were more 
likely to be male, not fasted, and have lower BMI, leptin 
and fasting glucose levels (Supplementary Table 5). The 
variables used in the imputation models are presented 
in Supplementary Table 6 and distributions of imputed 
variables in Supplementary Table 7.
There was no association between plasma cortisol 
and CVD incidence in the unadjusted model of all 
participants (Table 2). However, there was a positive 
association between morning plasma cortisol and CVD 
when including only participants with cortisol assessed 
Table 1 Characteristics of cases and controls in the combined VIP, MONICA and MSP cohort and BWHHS cohort. Means and 
standard deviations are presented for continuous variables. The number and percentage of individuals are presented for binary 
variables. Hypertensive was generated as blood pressure at examination ≥160/90 mmHg and/or taking antihypertensive 
medication. The P value from VIP, MONICA and MSP is from a conditional logistic regression model accounting for the matched 
nature of the data.
 VIP, MONICA and MSP BWHHS
Cases of ICHD (n = 905) Controls (n = 1717) P Cases of ICHD (n = 169) Controls (n = 327) P
Cortisol, nmol/L (s.d.) 524 (193) 527 (183) 0.85 526 (222) 530 (207) 0.58
Male, n (%) 655 (72) 1236 (72) – 0 (0) 0 (0) –
Age, years (s.d.) 54.5 (7.8) 54.3 (7.9) 0.11 70.4 (5.5) 70.1 (5.3) 0.47
BMI, kg/m2 (s.d.) 27.0 (3.9) 25.9 (3.6) <0.0001 28.1 (4.9) 27.4 (4.5) 0.14
FGL, mmol/L (s.d.) 5.63 (1.70) 5.36 (1.12) <0.0001 6.29 (2.17) 6.20 (1.99) 0.65
Total cholesterol, mmol/L (s.d.) 6.54 (1.30) 6.17 (1.25) <0.0001 6.76 (1.41) 6.63 (1.13) 0.27
HDL cholesterol, mmol/L (s.d.) 1.25 (0.98) 1.37 (0.92) 0.18 1.53 (0.42) 1.68 (0.47) 0.0003
Triglycerides, mmol/L (s.d.) 1.89 (1.27) 1.54 (0.87) <0.0001 2.10 (1.02) 1.87 (1.00) 0.005
SBP, mmHg (s.d.) 142 (19) 135 (17) <0.0001 153 (22) 148 (27) 0.05
DBP, mmHg (s.d.) 89 (10) 85 (9) <0.0001 81 (11) 80 (12) 0.52
Hypertensive, n (%) 574 (72) 752 (50) <0.0001 136 (80) 232 (71) 0.02
Ever smoked, n (%) 282 (33) 337 (20) <0.0001 90 (53) 138 (42) 0.02
BMI, body mass index; DBP, Diastolic blood pressure; FGL, fasting glucose level; HDL, high-density lipoprotein; ICHD, incident CHD; SBP, Systolic blood 
pressure. 
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between 0700 h and 1100 h (cases = 297, controls = 445), 
which was strengthened when adjusting for potential 
confounders (cases = 268, controls = 396) (Table 2). When 
the analysis was restricted to participants with complete 
data, there was evidence of a positive association in all 
models (Supplementary Table 1). The effect that each 
confounder has on the effect estimate can be seen in the 
one-at-a-time analysis with BMI having the largest effect 
in the observed (Supplementary Table 2) and imputed 
(Supplementary Table 3) data. The estimate obtained 
from the imputed data supported an association between 
higher morning plasma cortisol and CVD, but with an 
attenuated estimate in the adjusted model (OR 1.12, 95% 
CI 0.99–1.26) (Supplementary Table 8).
When the adjusted analysis was stratified by outcome 
(MI or stroke) the association between morning plasma 
cortisol and MI appeared to be stronger (OR 1.85, 95% 
CI 1.28–2.68) than with stroke (OR 1.08, 95% CI 0.84–
1.39); P = 0.01 for difference between the two estimates. 
There was no strong statistical evidence to suggest the 
association differed by sex (P = 0.36).
British Women’s Heart and Health Study (BWHHS)
There were 169 cases (111 non-fatal and 58 fatal) and 
363 controls included in the analysis of the BWHHS 
nested case–control study. Those with CHD had higher 
triglyceride levels and systolic blood pressure and lower 
HDL cholesterol levels; they were more likely to have 
hypertension and to have ever smoked (Table 1). The 
pattern of associations was similar to that in the VIP, 
MONICA and MSP studies, with little evidence of an 
association in unadjusted analyses of the whole study 
population and a positive association emerging as analyses 
were restricted to those with a sample taken between 
0700 h and 1100 h and after adjustment for confounders 
(Table 2). Estimates in BWHHS were less precise than in 
VIP, MONICA and MSP with 95% confidence intervals 
including the null value.
Meta-analysis of prospective studies
By combining data from the previously published 
analyses of the Caerphilly Study and Vietnam Experience 
Study with data from the VIP, MONICA and MSP cohorts 
and BWHHS cohort, a total of 7376 individuals (696 CVD 
events (fatal and non-fatal), 6680 controls) were included. 
The estimate from the Vietnam Experience Study was 
from an unadjusted regression model as that was all that 
was available. The other estimates were from models 
adjusting for potential confounders (Supplementary 
Table 9). A 1 s.d. higher cortisol was associated with 18% 
higher odds of experiencing a CVD event (OR: 1.18, 95% 
CI: 1.06–1.31) (Fig. 1). There was no strong evidence 
of heterogeneity (χ2[3] = 3.14, P = 0.37, I2 = 5% (95% CI: 
0–86%), and the positive association remained in a leave-
one-out analysis (Supplementary Table 10). Though power 
for these analyses is low, we found no strong evidence of 
association between study effect size estimate and mean 
participant age (P = 0.64) or percentage male (P = 0.93).
Visual inspection of a funnel plot of the effect size 
(lnOR) against the standard error of the effect size (lnOR) 
suggested asymmetry (Supplementary Fig. 1), indicating 
that some small studies that were consistent with a small 
or null association between cortisol and risk of CVD may 
be missing. Egger’s test did not provide evidence of small 
study bias (P = 0.32), although this test has low statistical 
power given the low number of studies included.
One- and two-sample Mendelian 
randomization analyses
In the VIP, MONICA and MSP cohort, there was no 
strong evidence of an association between the SNPs 
Table 2 Associations of plasma cortisol with CVD in the combined VIP, MONICA and MSP cohort and BWHHS cohort. All models 
included the matching variables of age; for VIP, MONICA and MSP, models also included the matching variables of sex, study and 
baseline assessment date. Adjusted models also included BMI, smoking and time of sampling in the regression models. Analyses 
were repeated restricted to individuals with blood sampling time between 0700 h and 1100 h.
VIP, MONICA and MSP BWHHS
Cases Controls OR (95% CI) P Cases Controls OR (95% CI) P
Unadjusted 905 1717 1.00 (0.91–1.09) 0.91 169 327 0.95 (0.78–1.14) 0.55
Adjusted 323 492 1.19 (1.01–1.41) 0.04 154 313 0.99 (0.80–1.22) 0.92
0700 h–1100 h         
 Unadjusted 297 445 1.17 (0.99–1.39) 0.07 45 91 1.22 (0.81–1.85) 0.34
 Adjusted 268 396 1.31 (1.07–1.60) 0.009 45 89 1.13 (0.72–1.76) 0.59
CI, confidence intervals; OR, odds ratio; P, P value.
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comprising the instrumental variable with any of the 
matching variables (age, sex, survey date, cohort) or 
potential confounders (BMI, sampling time, smoking) 
either individually or when combined in a fixed-effects or 
random-effects meta-analysis (Supplementary Table 11). 
In publicly available GWAS consortia the instrumental 
variable was positively associated with type 2 diabetes 
and negatively associated with being overweight, LDL 
cholesterol and cigarettes smoked per day (Supplementary 
Table 12). The Mendelian randomization analysis in 
the VIP, MONICA and MSP cohort suggested a positive 
effect of morning plasma cortisol on CVD risk (OR: 1.33, 
95% CI: 0.26–6.73), but this had a wide 95% confidence 
interval given the small sample size.
Using publicly available data, two-sample Mendelian 
randomization analysis provided evidence that each 
SD increase in morning plasma cortisol increased CHD: 
OR: 1.06, 95% CI: 0.98–1.15 (Fig. 2). There was no 
strong statistical evidence of heterogeneity between the 
instrumental variable effect estimate for each SNP (Q 
statistic = 0.88, P = 0.64). Estimates obtained from the 
additional Mendelian randomization analyses, including 
multivariable Mendelian randomization, lacked precision 
but consistent with the positive association obtained in 
the main analyses (Supplementary Tables 13 and 14).
Discussion
Previous prospective studies have reported positive 
associations between morning plasma cortisol and later 
CVD risk but a lack of precision of the effect estimate cast 
doubt on the importance of cortisol (13, 14, 15). Moreover, 
these reports focused on associations with CVD of the ratio 
of cortisol to testosterone (13), estradiol (14) and DHEAS 
(15) which are of questionable biological relevance. 
Here, we focused on morning plasma cortisol and were 
able to obtain precise estimates of its association with 
incident CVD/CHD by undertaking analyses in two new 
Figure 1
Meta-analysis of prospective multivariable regression 
association of morning plasma cortisol with cardiovascular 
disease. Meta-analysis provides evidence that a 1 s.d. increase 
of morning plasma cortisol is associated with 18% higher risk 
of later cardiovascular disease (odds ratio (OR) 1.18 95% CI 
1.06–1.31, P = 0.002). The VIP, MONICA and MSP study 
consisted of 268 cases and 396 controls; the BWHHS consisted 
of 45 cases and 89 controls; the Caerphilly Study consisted of 
320 cases and 2003 controls; the Vietnam study consisted of 
63 cases and 4192 controls. The number of controls in the 
Caerphilly and Vietnam Experience studies was assumed to be 
all individuals who did not experience a CVD event or CVD 
death. An assumption was made that the standard deviation 
of cortisol in the Vietnam Experience Study was the same as 
the VIP, MONICA and MSP study; this allowed inclusion of the 
Vietnam Experience study. Bars represent individual study 
95% confidence intervals, with a central block proportional to 
study size. The summary diamond represents the pooled 
effect size estimate and 95% CI. Weights are from random-
effects analysis. aRegression model included age, survey date, 
cohort, smoking, BMI and sampling time. bRegression model 
included age, smoking, BMI and sampling time. cRegression 
model including age, smoking status, sampling time, adult 
social class, alcohol consumption, height, FEV1/height2, 
fibrinogen (log transformed), white cell count (log 
transformed). dEstimate from unadjusted regression model.
Figure 2
Effect estimate of genetically elevated morning plasma cortisol 
on risk of CHD. The forest plot shows odds ratios and 95% 
confidence intervals for CHD per standard deviation increase 
in morning plasma cortisol. The overall genetic effect was 
estimated using random-effects meta-analysis of Wald ratio 
estimates. The genetic effect was estimated using data from 
the meta-analysis of 34,541 CHD cases and 261,984 controls 
from UK Biobank and 88,192 cases and 162,544 controls from 
CARDIoGRAMplusC4D (29).
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(previously unpublished) prospective nested case–control 
studies and pooling those results with existing published 
prospective studies in a random-effects meta-analysis. 
Following adjustment for key confounders (age, sex, BMI, 
smoking) where possible we found that a 1 s.d. higher 
morning plasma cortisol was associated with 18% higher 
odds of incident CVD/CHD. Furthermore, evidence from 
the Mendelian randomization analyses was consistent 
with these multivariable results, supporting a positive 
causal effect of morning cortisol levels on CVD/CHD. 
Given the key sources of biases in these two approaches 
are different – residual confounding in the multivariable 
regression analyses and horizontal pleiotropy, where a 
genetic variant influences multiple outcomes through 
independent pathways, in the Mendelian randomization 
analyses – the consistent finding with each strengthens 
the conclusion that there is a causal effect (31). Thus, our 
findings support the development of interventions that 
effectively lower cortisol as a means of reducing risk of 
CVD (32).
Plasma cortisol has a circadian rhythm with a peak on 
waking. In earlier studies, we found that several metabolic 
cardiovascular risk factors, such as blood glucose and 
blood pressure, were more closely associated with morning 
plasma cortisol than with other measurements such as 
24-h urinary cortisol metabolites (33), and that these 
associations are strengthened by adjusting for the time of 
sampling, at least for samples obtained in the morning 
(34). We therefore used morning samples, adjusted for time 
of sampling, in our previous GWAMA which identified 
genetic variants associated with morning plasma cortisol 
(17). Here, in multivariable regression analyses in both 
of the two independent studies, a positive association 
of cortisol with CVD/CHD was only observed when we 
excluded participants with samples outside of the 0700 
to 1100 h time range. This may be because afternoon 
cortisol values have less inter-individual variability or 
because morning cortisol better reflects the reactivity of 
the hypothalamic–pituitary–adrenal axis or contributes 
more to the tissue actions of cortisol.
There is also some consistency of findings between 
cortisol measured in other sample types. The cumulative 
exposure to cortisol over many weeks or months has 
been assessed by measuring cortisol in hair, which has 
also been reported recently to be associated with self-
reported history of CVD in a retrospective cohort study, 
with a comparable magnitude of effect as traditional risk 
factors (OR: 2.7 for highest cortisol quartile compared to 
lowest quartile, compared with hypertension (OR: 2.5), 
abdominal obesity (OR: 2.2) and diabetes mellitus (OR 
3.1)) (35, 36). Flatter slopes in decline of saliva cortisol 
across the day in the prospective Whitehall II cohort 
study among 4047 civil servants were associated with 
higher risk of cardiovascular deaths (hazard ratio for 1 s.d. 
reduction in slope steepness = 1.87; 95% CI: 1.32–2.64) 
(37). Also, higher 24-h urinary cortisol levels, as measured 
in 861 participants who were part of the prospective 
InCHIANTI study, were associated with higher risk of 
dying of CVD (highest tertile compared with lowest 
tertile, hazard ratio = 5.00; 95% CI: 2.02–12.37) (38). Of 
course, we recognise the potential for publication bias in 
this area so adding genetic evidence to our findings was 
deemed important.
Mendelian randomization analysis is less likely 
to be biased by confounding or reverse causation and 
suggests that the elevated morning plasma cortisol that is 
associated with CVD/CHD is unlikely to be attributed to, 
for example, a response of the hypothalamic–pituitary–
adrenal axis to chronic inflammation of subclinical 
cardiovascular disease. There was no strong evidence of 
an association between the instrumental variable used in 
the Mendelian randomization analyses and the potential 
confounders included in the multivariable regression 
analyses. In addition, estimates from the multivariable 
Mendelian randomization analyses were consistent with 
the positive association obtained in the main analyses. 
The three SNPs comprising the instrumental variable were 
not in LD (r2 < 0.1) with a SNP (rs112635299) associated 
with CHD in the same locus (29). This suggests it is 
unlikely that horizontal pleiotropy is biasing the estimate 
between morning plasma cortisol and CHD observed 
in our two-sample Mendelian randomization analysis. 
Further, consistent estimates were obtained using 
the Wald ratio, inverse variance weighted, likelihood 
method and weighted median approaches. The genetic 
variants comprising the instrument in the Mendelian 
randomization analyses explain 0.5% variance in morning 
plasma cortisol. This may cause weak instrument bias 
which in the two-sample analyses will bias the estimate 
towards the null.
Greater clarity in understanding the causal pathway 
between elevated cortisol and CHD will be achieved by 
firstly, identifying additional variants associated with 
cortisol to strengthen the instrumental variable used in 
Mendelian randomization and enable use of additional 
methods (39, 40, 41) more adept at handling pleiotropy 
and secondly, validating the instrumental variable for 
plasma cortisol in non-European populations justifying 
the analysis of larger outcome datasets of mixed ancestry 
leading to greater precision of causal estimates.
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Cortisol acts through intracellular glucocorticoid and 
mineralocorticoid receptors to modulate fuel metabolism, 
cardiovascular homeostasis and inflammation. As such 
there are multiple pathways through which cortisol may 
be increasing CVD risk. The effects of cortisol on CVD may 
be mediated by high blood pressure and glucose levels. 
If this is the case, interventions that target the source 
of the problem, cortisol, may prevent use of multiple, 
subsequent interventions (i.e. blood pressure lowering 
and glucose lowering medications). However, there is also 
evidence that cortisol is exerting a direct effect on CVD 
risk, independent of established CVD risk factors. In this 
case, current treatments will not be effective in reducing 
CVD risk in individuals with high cortisol levels.
Our stratified analysis suggested there may be a 
stronger association of morning plasma cortisol with 
CHD than stroke; although this was not conclusive, it is 
consistent with the higher risk of CHD, rather than stroke, 
observed in patients exposed to exogenous glucocorticoids 
(6, 42). The underlying mechanism for this difference is 
unknown.
The strengths of our studies include the meta-analysis 
of multiple cohorts, reducing sampling bias and increasing 
statistical power, and the careful case classification and use 
of matched controls in the VIP, MONICA and MSP cohort. 
A further strength is the consistency between different 
approaches, with the positive prospective association 
supported by findings from the Mendelian randomization 
analyses (31).
Limitations include the wide range of sampling times 
and large number of missing data for sampling time in the 
VIP, MONICA and MSP cohort, which reduced precision 
and potentially introduced bias when estimating the 
association between cortisol and CVD. To address these 
limitations, we performed multivariable imputation 
to replace missing sampling times with values imputed 
from the observed data. When the estimate from the 
imputed dataset, rather than the observed data, was 
used to contribute to the meta-analysis then the positive 
association remained (OR: 1.12, 95% CI: 1.03–1.22). 
Given the known importance of sampling time for 
plasma cortisol, it was not unexpected that there was no 
association between cortisol and CVD in the unadjusted 
analysis. The other cardiovascular risk factors that were 
measured and adjusted for in the studies included in 
the meta-analysis was not comprehensive so that the 
adjustments may have been incomplete. The Mendelian 
randomization within the VIP, MONICA and MSP cohort, 
which aimed to establish three-way associations between 
genotype, plasma cortisol and CVD, was under-powered.
Improving our understanding of the underlying 
mechanisms of CVD, as well as identifying biomarkers, is of 
public health importance as it can lead to the development 
of novel pharmaceutical treatments and guide targeted 
interventions for those most at risk. The current data 
suggest that strategies targeted at lowering cortisol 
action may reduce risk of CVD. Reducing cortisol action 
safely is challenging, given that the anti-inflammatory 
properties of cortisol are essential to survival during, for 
example, severe infection. However, approaches which 
target tissue-specific cortisol action, such as inhibition of 
the cortisol regenerating enzyme 11βHSD1, have shown 
modest improvements in glycaemic control, lipid profile 
and blood pressure in phase II clinical trials for type 2 
diabetes and arguably should be evaluated for their effects 
on CVD (43).
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